These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 17894369)

  • 21. Influence of crystal form of ipratropium bromide on micronisation and aerosolisation behaviour in dry powder inhaler formulations.
    Shur J; Kubavat HA; Ruecroft G; Hipkiss D; Price R
    J Pharm Pharmacol; 2012 Sep; 64(9):1326-36. PubMed ID: 22881444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
    Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
    Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aerosolisation of beclomethasone dipropionate using spray dried lactose/polyethylene glycol carriers.
    Gilani K; Rouholamini Najafabadi A; Barghi M; Rafiee-Tehrani M
    Eur J Pharm Biopharm; 2004 Nov; 58(3):595-606. PubMed ID: 15451534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
    Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
    Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterizing the Surface Roughness Length Scales of Lactose Carrier Particles in Dry Powder Inhalers.
    Tan BMJ; Chan LW; Heng PWS
    Mol Pharm; 2018 Apr; 15(4):1635-1642. PubMed ID: 29490144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient.
    Kaialy W; Martin GP; Ticehurst MD; Momin MN; Nokhodchi A
    Int J Pharm; 2010 Jun; 392(1-2):178-88. PubMed ID: 20363301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers.
    Young PM; Wood O; Ooi J; Traini D
    Int J Pharm; 2011 Sep; 416(1):129-35. PubMed ID: 21708238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations.
    Price R; Young PM; Edge S; Staniforth JN
    Int J Pharm; 2002 Oct; 246(1-2):47-59. PubMed ID: 12270608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
    Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
    J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immobilization of fine particles on lactose carrier by precision coating and its effect on the performance of dry powder formulations.
    Chan LW; Lim LT; Heng PW
    J Pharm Sci; 2003 May; 92(5):975-84. PubMed ID: 12712417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of milling and sieving on functionality of dry powder inhalation products.
    Steckel H; Markefka P; teWierik H; Kammelar R
    Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of carrier on the performance of dry powder inhalers.
    Saint-Lorant G; Leterme P; Gayot A; Flament MP
    Int J Pharm; 2007 Apr; 334(1-2):85-91. PubMed ID: 17113733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
    Donovan MJ; Smyth HD
    Int J Pharm; 2010 Dec; 402(1-2):1-9. PubMed ID: 20816928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Towards the optimisation and adaptation of dry powder inhalers.
    Cui Y; Schmalfuß S; Zellnitz S; Sommerfeld M; Urbanetz N
    Int J Pharm; 2014 Aug; 470(1-2):120-32. PubMed ID: 24792975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functionalization of lactose as a biological carrier for bovine serum albumin by electrospraying.
    Tavares Cardoso MA; Talebi M; Soares PA; Yurteri CU; van Ommen JR
    Int J Pharm; 2011 Jul; 414(1-2):1-5. PubMed ID: 21536114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler.
    Kaialy W; Momin MN; Ticehurst MD; Murphy J; Nokhodchi A
    Colloids Surf B Biointerfaces; 2010 Sep; 79(2):345-56. PubMed ID: 20537870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the role of particle morphology in pharmaceutical powder aerosols?
    Chan HK
    Expert Opin Drug Deliv; 2008 Aug; 5(8):909-14. PubMed ID: 18712999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance.
    Young PM; Chan HK; Chiou H; Edge S; Tee TH; Traini D
    J Pharm Sci; 2007 May; 96(5):1331-41. PubMed ID: 17455362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.